Get started
Author

Sara Monico

Delisting HCV ‐infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting
2018 · Giovanni Perricone, Christophe Duvoux, et al. · Liver International · 76
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension
2022 · Elisabetta Degasperi, Maria Paola Anolli, et al. · Journal of Hepatology · 68
The pattern of pegylated interferon-α2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype
2009 · Alessio Aghemo, Maria Grazia Rumi, et al. · Antiviral Therapy · 33
PDF
Bridging all oral DAA therapy from wait time to post‐liver transplant to improve HCV eradication?
2014 · Maria Francesca Donato, Sara Monico, et al. · Liver International · 27
Long‐term outcomes of direct acting antivirals in post‐transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis
2017 · R. Vukotic, F. Conti, et al. · Journal of Viral Hepatitis · 14
PDF
Quantification of serum HDV RNA by Robogene 2.0 in HDV patients is significantly influenced by the extraction methods
2024 · Maria Paola Anolli, Sara Uceda Renteria, et al. · Liver International · 13
PDF
Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients
2013 · L. Ronzoni, A. Aghemo, et al. · Journal of Viral Hepatitis · 11
Ribavirin Impairs Salivary Gland Function in Hepatitis C Patients During Combination Treatment With Pegylated Interferon Alfa-2a
2011 · Alessio Aghemo, Maria Grazia Rumi, et al. · Hepatitis Monthly · 11
Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta
2024 · Elisabetta Degasperi, Caroline Scholtes, et al. · Journal of Hepatology · 9
Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV
2024 · Maria Paola Anolli, Sara Uceda Renteria, et al. · JHEP Reports · 8
PDF
Development and Validation of a PIVKA ‐ II ‐Based Model for HCC Risk Stratification in Patients With HCV ‐Related Cirrhosis Successfully Treated With DAA
2024 · Gian Paolo Caviglia, Piero Fariselli, et al. · Alimentary Pharmacology & Therapeutics · 8
PDF
Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B
2025 · Maria Kalafateli, Roberta Forlano, et al. · Clinical Gastroenterology and Hepatology · 7
PDF
Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide
2024 · Pierluigi Toniutto, Edmondo Falleti, et al. · Journal of Hepatology · 7
Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients
2011 · Alessio Aghemo, Maria Grazia Rumi, et al. · Hepatitis Monthly · 7
PDF
Bulevirtide monotherapy prevents liver decompensation and reduces mortality in patients with HDV-related cirrhosis: a case control study with propensity score weighted analysis
2024 · E. Degasperi, A. De Silvestri, et al. · Digestive and Liver Disease · 6
Directly acting antivirals are safe and effective in HCV positive patients aged 80 years and older: a multicenter real-life study
2021 · Nicola Pugliese, Alessia Giorgini, et al. · Expert Opinion on Drug Safety · 6
TOP-265 Virological outcomes in patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy for 144 weeks: a subanalysis of the retrospective multicenter european study (Save-D)
2025 · Elisabetta Degasperi, Maria Paola Anolli, et al. · Journal of Hepatology · 4
HBsAg Isoforms as Innovative Biomarkers in Predicting Virological Response to Bulevirtide in Patients With Chronic Hepatitis D
2025 · Stefano D'Anna, Romina Salpini, et al. · Liver International · 4
Long‐term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years
2023 · Elisa Farina, Alessandro Loglio, et al. · Alimentary Pharmacology & Therapeutics · 4
Delisting of liver transplant candidates with chronic hepatitis C virus infection after viral eradication: outcome after delisting: a European study
2017 · L.S. Belli, M. Berenguer, et al. · Journal of Hepatology · 4
OS-120 Bulevirtide monotherapy prevents liver decompensation and reduces mortality in patients with HDV-related cirrhosis: a case control study with propensity score weighted analysis
2024 · Elisabetta Degasperi, Annalisa De Silvestri, et al. · Journal of Hepatology · 3
Trientine tetrahydrochloride versus d-Penicillamine for the management of patients with Wilson Disease: results from the CHELATE trial a year after randomisation
2022 · M. Zuin, A. Czlonkowska, et al. · Digestive and Liver Disease · 2
Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: Safety and survival
2018 · F. Invernizzi, M. Iavarone, et al. · Digestive and Liver Disease · 2
Twelve week post-treatment undetectable hepatitis C virus (HCV)-RNA by PCR assay predicts a sustained virological response to anti-HCV therapy independently from immunological status of the infected patients
2012 · M. F. Donato, A. J. Bastiampillai, et al. · Journal of Antimicrobial Chemotherapy · 2
Anemia during Pegylated Interferon-Ribavirin Therapy Results from Both Increase Suppression of Erythroid Differentiation and Hemolysis
2008 · Luisa Ronzoni, Alessio Aghemo, et al. · Blood · 2
Works count: 64
Citation count: 348
H-index: 9
I10-index: 8
Year
Topic
Type